| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
70,730,000 |
| Market
Cap: |
201.58(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.1 - $4.01 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ADC Therapeutics is a biotechnology company. Co. is focused on the development of antibody drug conjugates, including research, development, human clinical trials, regulatory approval and commercialization. Antibody drug conjugates (ADCs) are drug constructs which combine monoclonal antibodies specific to particular types of cells with cytotoxic molecules or warheads which seek to kill cancer cells to which the ADC attaches. Co.'s hematology franchise comprises three clinical-stage product candidates, Lonca, Cami and ADCT-602. Co.'s solid tumor franchise comprises two clinical-stage product candidates, Cami and ADCT-601, and two preclinical product candidates, ADCT-901 and ADCT-701.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
200,000 |
1,000,000 |
| Total Buy Value |
$0 |
$0 |
$609,000 |
$2,857,000 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
2 |
4 |
| Total Shares Sold |
0 |
0 |
25,352 |
87,130 |
| Total Sell Value |
$0 |
$0 |
$52,479 |
$278,292 |
| Total People Sold |
0 |
0 |
1 |
9 |
| Total Sell Transactions |
0 |
0 |
1 |
9 |
| End Date |
2025-04-03 |
2024-12-31 |
2024-07-02 |
2023-07-03 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sandor Victor |
Director |
– • – |
2025-06-13 |
4 |
D |
$3.58 |
$45,108 |
D/D |
(12,600) |
108,286 |
|
- |
|
| Hug Peter |
Director |
– • – |
2025-06-13 |
4 |
D |
$3.58 |
$7,676 |
D/D |
(2,144) |
220,500 |
|
- |
|
| Squarer Ron |
Director |
– • – |
2025-06-13 |
4 |
D |
$3.58 |
$54,359 |
D/D |
(15,184) |
93,627 |
|
- |
|
| Azelby Robert |
Director |
– • – |
2025-06-13 |
4 |
D |
$3.58 |
$45,108 |
D/D |
(12,600) |
80,405 |
|
- |
|
| Bizzari Jean-Pierre |
Director |
– • – |
2025-06-13 |
4 |
D |
$3.58 |
$45,108 |
D/D |
(12,600) |
106,902 |
|
- |
|
| Monges Viviane |
Director |
– • – |
2025-06-13 |
4 |
D |
$3.58 |
$9,251 |
D/D |
(2,584) |
144,043 |
|
- |
|
| Hug Peter |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
222,644 |
|
- |
|
| Azelby Robert |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
93,005 |
|
- |
|
| Monges Viviane |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
146,627 |
|
- |
|
| Squarer Ron |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
108,811 |
|
- |
|
| Coughlin Timothy P |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
40,000 |
|
- |
|
| Bizzari Jean-Pierre |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
119,502 |
|
- |
|
| Sandor Victor |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
120,886 |
|
- |
|
| Wild Hans Peter |
10% Owner |
– – • |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,788,944 |
9,788,944 |
|
- |
|
| Pfisterer Thomas |
See Explanations |
– – – |
2025-05-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(451,856) |
173,899 |
|
- |
|
| Mallik Ameet |
Chief Executive Officer |
• • – |
2025-05-06 |
4 |
D |
$1.29 |
$34,518 |
D/D |
(26,758) |
1,552,247 |
|
- |
|
| Mallik Ameet |
Chief Executive Officer |
• • – |
2025-02-13 |
4 |
A |
$1.61 |
$1,046,500 |
D/D |
650,000 |
1,579,005 |
|
- |
|
| Zaki Mohamed |
Chief Medical Officer |
• – – |
2025-02-13 |
4 |
A |
$1.61 |
$370,300 |
D/D |
230,000 |
462,888 |
|
- |
|
| Graham Peter J |
Chief Legal Officer |
• – – |
2025-02-13 |
4 |
A |
$1.61 |
$354,200 |
D/D |
220,000 |
408,542 |
|
- |
|
| Kallebo Lisa Michelle |
Chief Accounting Officer |
• – – |
2025-02-13 |
4 |
A |
$1.61 |
$67,459 |
D/D |
41,900 |
77,897 |
|
- |
|
| Carmona Jose |
Chief Financial Officer |
• – – |
2025-02-13 |
4 |
A |
$1.61 |
$386,400 |
D/D |
240,000 |
541,892 |
|
- |
|
| Redco Ii Master Fund, L.p. |
10% Owner |
– – • |
2024-12-11 |
4 |
B |
$2.28 |
$304,500 |
D/D |
100,000 |
13,145,712 |
2.45 |
-39% |
|
| Redco Ii Master Fund, L.p. |
10% Owner |
– – • |
2024-12-11 |
4 |
B |
$2.28 |
$304,500 |
I/I |
100,000 |
15,666,731 |
1.5 |
-39% |
|
| Mallik Ameet |
Chief Executive Officer |
• • – |
2024-12-06 |
4 |
D |
$3.13 |
$746,014 |
D/D |
(238,343) |
929,005 |
|
- |
|
| Graham Peter J |
Chief Legal Officer |
• – – |
2024-12-06 |
4 |
D |
$3.13 |
$129,764 |
D/D |
(41,458) |
188,542 |
|
- |
|
66 Records found
|
|
Page 1 of 3 |
|
|
0.05 (1.79%) 
